Argus upgraded Teva to Buy from Hold.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- FTC sends Teva civil investigative demand over patents, WaPo reports
- Federal Court allows Vanda’s HETLIOZ patent lawsuit to proceed
- Teva announces data from fourth interim analysis of PEARL study of AJOVY
- Teva price target raised to $23 from $19 at Jefferies
- Teva’s agreement with the ITA has no impact on 2024 financial outlook